PriceTargets.com logo

Jasper Therapeutics - JSPR Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $25.63
  • Forecasted Upside: 1,277.69%
  • Number of Analysts: 11
  • Breakdown:
  • 1 Sell Ratings
  • 4 Hold Ratings
  • 6 Buy Ratings
  • 0 Strong Buy Ratings
$1.86 As of 12/4/2025 05:00 PM ET
▲ +0.21 (12.73%)

This chart shows the closing price for JSPR by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Jasper Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for JSPR and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for JSPR

Analyst Price Target is $25.63
▲ +1,277.69% Upside Potential
This price target is based on 11 analysts offering 12 month price targets for Jasper Therapeutics in the last 3 months. The average price target is $25.63, with a high forecast of $65.00 and a low forecast of $5.00. The average price target represents a 1,277.69% upside from the last price of $1.86.

This chart shows the closing price for JSPR for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 11 investment analysts is to hold stock in Jasper Therapeutics. This rating has held steady since September 2025, when it changed from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/12/2024
  • 0 strong buy ratings
  • 10 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/10/2024
  • 0 strong buy ratings
  • 10 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/9/2024
  • 0 strong buy ratings
  • 10 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/9/2025
  • 0 strong buy ratings
  • 10 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/7/2025
  • 0 strong buy ratings
  • 6 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
9/5/2025
  • 0 strong buy ratings
  • 6 buy ratings
  • 4 hold ratings
  • 1 sell ratings
Ratings as of
11/4/2025
  • 0 strong buy ratings
  • 6 buy ratings
  • 4 hold ratings
  • 1 sell ratings
Ratings as of
12/4/2025

Latest Recommendations

  • 0 strong buy ratings
  • 6 buy ratings
  • 4 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
10/8/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
9/27/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
9/22/2025Evercore ISILower TargetOutperform ➝ Outperform$20.00 ➝ $14.00
9/22/2025JMP SecuritiesLower TargetMarket Outperform ➝ Market Outperform$12.00 ➝ $6.00
9/22/2025BTIG ResearchLower TargetBuy ➝ Buy$20.00 ➝ $7.00
8/15/2025UBS GroupLower TargetBuy ➝ Buy$29.00 ➝ $25.00
7/8/2025Royal Bank Of CanadaDowngradeOutperform ➝ Sector Perform$5.00
7/8/2025JMP SecuritiesLower TargetMarket Outperform ➝ Market Outperform$70.00 ➝ $12.00
7/8/2025Evercore ISILower TargetOutperform ➝ Outperform$50.00 ➝ $20.00
7/8/2025BMO Capital MarketsReiterated RatingOutperform ➝ Market Perform
7/7/2025HC WainwrightLower TargetBuy ➝ Buy$40.00 ➝ $20.00
7/7/2025BTIG ResearchLower TargetBuy ➝ Buy$64.00 ➝ $20.00
7/7/2025Cantor FitzgeraldDowngradeOverweight ➝ Neutral
7/7/2025William BlairReiterated RatingOutperform ➝ Market Perform
5/15/2025OppenheimerLower TargetOutperform ➝ Outperform$80.00 ➝ $65.00
5/13/2025UBS GroupLower TargetBuy ➝ Buy$38.00 ➝ $33.00
3/11/2025HC WainwrightReiterated RatingBuy ➝ Buy$40.00 ➝ $40.00
2/13/2025UBS GroupInitiated CoverageBuy$38.00
1/10/2025HC WainwrightLower TargetBuy ➝ Buy$60.00 ➝ $40.00
1/9/2025Royal Bank Of CanadaLower TargetOutperform ➝ Outperform$68.00 ➝ $48.00
1/6/2025JMP SecuritiesReiterated RatingMarket Outperform ➝ Market Outperform$70.00 ➝ $70.00
12/23/2024Royal Bank Of CanadaReiterated RatingOutperform ➝ Outperform$68.00 ➝ $68.00
12/6/2024BMO Capital MarketsInitiated CoverageOutperform$63.00
10/24/2024HC WainwrightReiterated RatingBuy ➝ Buy$65.00 ➝ $65.00
10/15/2024JMP SecuritiesReiterated RatingMarket Outperform ➝ Market Outperform$70.00 ➝ $70.00
10/15/2024HC WainwrightReiterated RatingBuy ➝ Buy$65.00 ➝ $65.00
9/27/2024JMP SecuritiesReiterated RatingMarket Outperform ➝ Market Outperform$70.00 ➝ $70.00
9/9/2024Cantor FitzgeraldReiterated RatingOverweight
9/9/2024JMP SecuritiesInitiated CoverageOutperform$70.00
8/26/2024Evercore ISIReiterated RatingOutperform ➝ Outperform$65.00 ➝ $65.00
8/14/2024Royal Bank Of CanadaLower TargetOutperform ➝ Outperform$70.00 ➝ $68.00
8/13/2024HC WainwrightReiterated RatingBuy ➝ Buy$65.00 ➝ $65.00
8/5/2024HC WainwrightReiterated RatingBuy ➝ Buy$65.00 ➝ $65.00
7/8/2024BTIG ResearchInitiated CoverageBuy$90.00
6/27/2024Stifel NicolausInitiated CoverageBuy$86.00
6/18/2024Cantor FitzgeraldReiterated RatingOverweight
5/15/2024HC WainwrightReiterated RatingBuy ➝ Buy$65.00
5/6/2024HC WainwrightInitiated CoverageBuy$65.00
4/3/2024Evercore ISIInitiated CoverageOutperform$65.00
3/28/2024Royal Bank Of CanadaInitiated CoverageOutperform$70.00
3/18/2024TD CowenInitiated CoverageOutperform
3/7/2024OppenheimerReiterated RatingOutperform ➝ Outperform$80.00
11/8/2023William BlairReiterated RatingOutperform
10/12/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$60.00
8/14/2023Credit Suisse GroupReiterated RatingOutperform ➝ Outperform$40.00
8/11/2023Capital One FinancialInitiated CoverageOverweight$70.00
5/15/2023Cantor FitzgeraldReiterated RatingOverweight
3/9/2023Credit Suisse GroupReiterated RatingOutperform$40.00
3/9/2023Cantor FitzgeraldReiterated RatingOverweight$60.00
3/9/2023EF Hutton Acquisition Co. IReiterated RatingBuy$68.50
2/27/2023EF Hutton Acquisition Co. IReiterated RatingBuy$68.50
2/17/2023EF Hutton Acquisition Co. IReiterated RatingBuy$40.00 ➝ $68.50
2/7/2023Cantor FitzgeraldLower TargetOverweight$100.00 ➝ $60.00
1/11/2023EF Hutton Acquisition Co. IReiterated RatingBuy$40.00
1/11/2023Credit Suisse GroupLower TargetOutperform$70.00 ➝ $30.00
11/16/2022Credit Suisse GroupLower Target$70.00
11/14/2022OppenheimerLower TargetOutperform$210.00 ➝ $80.00
11/1/2022EF Hutton Acquisition Co. IInitiated CoverageBuy$40.00
7/13/2022Credit Suisse GroupLower TargetOutperform$90.00 ➝ $80.00
2/28/2022Cantor FitzgeraldInitiated CoverageOverweight$100.00
2/25/2022Credit Suisse GroupLower TargetOutperform$150.00 ➝ $100.00
11/8/2021Credit Suisse GroupInitiated CoverageOutperform$150.00
10/21/2021William BlairInitiated CoverageOutperform
10/20/2021BMO Capital MarketsInitiated CoverageOutperform$190.00
10/12/2021OppenheimerInitiated CoverageOutperform$210.00
(Data available from 12/4/2020 forward)

News Sentiment Rating

0.15 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 4 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/8/2025
  • 7 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/7/2025
  • 3 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/7/2025
  • 2 very positive mentions
  • 20 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
8/6/2025
  • 0 very positive mentions
  • 13 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/5/2025
  • 1 very positive mentions
  • 46 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Mentions as of
10/5/2025
  • 1 very positive mentions
  • 65 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
11/4/2025
  • 4 very positive mentions
  • 43 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/4/2025

Current Sentiment

  • 4 very positive mentions
  • 43 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Jasper Therapeutics logo
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and conditioning regimens for stem cell transplantation. In addition, it is also developing stem cell transplants for rare diseases such as sickle cell disease, fanconi anemia, chronic granulomatous diseases, and GATA2 MDS, and severe combined immunodeficiency. Jasper Therapeutics, Inc. is headquartered in Redwood City, California.
Read More

Today's Range

Now: $1.86
Low: $1.59
High: $1.89

50 Day Range

MA: $2.11
Low: $1.58
High: $2.60

52 Week Range

Now: $1.86
Low: $1.39
High: $23.89

Volume

1,962,350 shs

Average Volume

3,607,751 shs

Market Capitalization

$52.04 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

3.06

Frequently Asked Questions

What sell-side analysts currently cover shares of Jasper Therapeutics?

The following Wall Street research analysts have issued research reports on Jasper Therapeutics in the last year: BMO Capital Markets, BTIG Research, Cantor Fitzgerald, Evercore ISI, HC Wainwright, JMP Securities, Oppenheimer Holdings, Inc., Royal Bank Of Canada, UBS Group AG, Weiss Ratings, and William Blair.
View the latest analyst ratings for JSPR.

What is the current price target for Jasper Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Jasper Therapeutics in the last year. Their average twelve-month price target is $25.63, suggesting a possible upside of 1,277.7%. Oppenheimer Holdings, Inc. has the highest price target set, predicting JSPR will reach $65.00 in the next twelve months. Royal Bank Of Canada has the lowest price target set, forecasting a price of $5.00 for Jasper Therapeutics in the next year.
View the latest price targets for JSPR.

What is the current consensus analyst rating for Jasper Therapeutics?

Jasper Therapeutics currently has 1 sell rating, 4 hold ratings and 6 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in JSPR, but not buy more shares or sell existing shares.
View the latest ratings for JSPR.

What other companies compete with Jasper Therapeutics?

Other companies that are similar to Jasper Therapeutics include Quince Therapeutics, Maxpro Capital Acquisition, Neoleukin Therapeutics, Rani Therapeutics and Arcturus Therapeutics. Learn More about companies similar to Jasper Therapeutics.

How do I contact Jasper Therapeutics' investor relations team?

Jasper Therapeutics' physical mailing address is 1177 AVENUE OF THE AMERICAS FL 40, NEW YORK NY, 10036. The company's listed phone number is 650-549-1400 and its investor relations email address is [email protected]. The official website for Jasper Therapeutics is jaspertherapeutics.com. Learn More about contacing Jasper Therapeutics investor relations.